Bajaj Healthcare Ltd (IN:BAJAJHCARE)
:BAJAJHCARE
Want to see IN:BAJAJHCARE full AI Analyst Report?
Top Page
Bajaj Healthcare Ltd
(BAJAJHCARE)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹289.00
▼(-30.94% Downside)
Action:Reiterated
Date:05/13/26
The score is held back primarily by volatile profitability and weak cash conversion (frequent negative free cash flow), alongside a technically weak setup with the stock trading below key moving averages. A high P/E and low dividend yield further reduce the valuation support, partially offset by improved leverage and a modest FY2026 revenue rebound.
Positive Factors
Integrated manufacturing footprint (APIs, intermediates, formulations)
A vertically integrated manufacturing model spanning APIs, intermediates and finished dosages supports diversified revenue streams and customer types (domestic, export, contract CMO). This durability reduces single-segment exposure and enables scale advantages, long-term customer relationships and margin stability.
Negative Factors
Net margin compression and earnings volatility
Sharp swings in net margin and prior loss years indicate earnings are sensitive to below-the-line items, one-offs or cost shocks. Low and volatile net margins reduce retained earnings, weaken return metrics, and increase the company's exposure to adverse cycles over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated manufacturing footprint (APIs, intermediates, formulations)
A vertically integrated manufacturing model spanning APIs, intermediates and finished dosages supports diversified revenue streams and customer types (domestic, export, contract CMO). This durability reduces single-segment exposure and enables scale advantages, long-term customer relationships and margin stability.
Read all positive factors
Bajaj Healthcare Ltd (BAJAJHCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹10.06B
Dividend Yield0.24%
Average Volume (3M)4.99K
Price to Earnings (P/E)58.3
Beta (1Y)1.21
Revenue Growth12.61%
EPS Growth-61.60%
CountryIN
Employees1,049
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.39
Shares Outstanding33,662,663
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)1.72
Price to Sales (P/S)1.50
P/FCF Ratio-149.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bajaj Healthcare Ltd Business Overview & Revenue Model
Company Description
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, and supplies amino acids, nutritional supplements, and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceuticals, and food industries in India and intern...
How the Company Makes Money
Bajaj Healthcare makes money primarily by manufacturing and selling pharmaceutical products across multiple categories. Its core revenue streams typically include: (1) sales of active pharmaceutical ingredients (APIs) and pharmaceutical intermedia...
Bajaj Healthcare Ltd Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74B | 6.11B | 5.43B | 4.73B | 6.46B | 6.79B |
| Gross Profit | 2.18B | 2.04B | 1.71B | 2.14B | 1.33B | 1.84B |
| EBITDA | 1.03B | 1.05B | 1.02B | 406.24M | 1.22B | 1.20B |
| Net Income | 458.42M | 157.66M | 394.95M | -837.93M | 430.24M | 713.86M |
Balance Sheet | ||||||
| Total Assets | 8.39B | 9.23B | 8.33B | 7.65B | 9.01B | 7.21B |
| Cash, Cash Equivalents and Short-Term Investments | 140.05M | 379.87M | 44.51M | 29.29M | 192.29M | 19.75M |
| Total Debt | 2.38B | 2.49B | 2.23B | 3.33B | 4.15B | 2.57B |
| Total Liabilities | 3.52B | 3.90B | 3.67B | 4.87B | 5.34B | 3.93B |
| Stockholders Equity | 4.86B | 5.33B | 4.66B | 2.78B | 3.68B | 3.28B |
Cash Flow | ||||||
| Free Cash Flow | 392.01M | -61.26M | -173.16M | 620.08M | -1.46B | -786.19M |
| Operating Cash Flow | 501.85M | 372.23M | -57.78M | 922.94M | -223.24M | 6.86M |
| Investing Cash Flow | -198.00M | -480.91M | -153.21M | -112.45M | -934.27M | -747.98M |
| Financing Cash Flow | -210.12M | 455.00M | 215.28M | -965.96M | 1.31B | 618.46M |
Bajaj Healthcare Ltd Technical Analysis
Negative
418.50
Price Trends
314.90
Negative
344.98
Negative
396.53
Negative
Market Momentum
-10.14
Positive
43.96
Neutral
21.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAJAJHCARE, the sentiment is Negative. The current price of 418.5 is above the 20-day moving average (MA) of 314.60, above the 50-day MA of 314.90, and above the 200-day MA of 396.53, indicating a bearish trend. The MACD of -10.14 indicates Positive momentum. The RSI at 43.96 is Neutral, neither overbought nor oversold. The STOCH value of 21.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAJAJHCARE.
Bajaj Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹13.45B | 37.13 | ― | 1.24% | 6.89% | -23.34% | |
72 Outperform | ₹30.73B | 18.57 | ― | 0.28% | 7.19% | 82.31% | |
69 Neutral | ₹15.65B | 18.63 | ― | 0.44% | 6.91% | 104.46% | |
69 Neutral | ₹13.27B | 17.72 | ― | ― | 28.33% | 76.13% | |
60 Neutral | ₹9.02B | 22.95 | ― | 0.48% | -21.83% | -137.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹10.06B | 58.25 | ― | 0.24% | 12.61% | -61.60% |
* Healthcare Sector Average
IN:BAJAJHCARE
Bajaj Healthcare Ltd
304.25
-262.42
-46.31%
IN:BLISSGVS
Bliss Gvs Pharma Limited
294.95
169.47
135.06%
IN:HESTERBIO
Hester Biosciences Limited
1,879.90
117.76
6.68%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
211.70
1.34
0.64%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
14.27
-5.43
-27.56%
IN:THEMISMED
Themis Medicare Limited
99.15
-41.27
-29.39%
Bajaj Healthcare Ltd Corporate Events
Bajaj Healthcare Publishes FY26 Audited Results in Newspapers to Meet SEBI Norms
May 10, 2026
Bajaj Healthcare Ltd has published its audited financial results for the quarter and full year ended 31 March 2026 in the Financial Express and Mumbai Lakshadweep, in line with regulatory requirements. The disclosure, made under Regulation 47 of S...
Bajaj Healthcare Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Bajaj Healthcare Ltd has announced the closure of its trading window for company securities for all insiders, designated persons, and their immediate relatives from April 1, 2026. The window will remain shut until 48 hours after the release of the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.